Potential Lilly schizophrenia candidate fails to meet goal in late-stage trial
This article was originally published in Scrip
Executive Summary
Lilly said that its oral investigational glutamate 2 receptor agonist, pomaglumetad methionil (LY2140023), failed to meet its efficacy endpoint in a late-stage, placebo-controlled trial in the treatment of patients suffering an acute exacerbation of schizophrenia.